The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.

COVID-19 vaccines are playing a vital role in controlling the COVID-19 pandemic. As SARS-CoV-2 variants encoding mutations in the surface glycoprotein, Spike, continue to emerge, there is increased need to identify immunogens and vaccination regimens that provide the broadest and most durable immune responses. We compared the magnitude and breadth of the neutralizing antibody response, as well as levels of Spike-reactive memory B cells, in individuals receiving a second dose of BNT162b2 at a short (3-4 week) or extended interval (8-12 weeks) and following a third vaccination approximately 6-8 months later. We show that whilst an extended interval between the first two vaccinations can greatly increase the breadth of the immune response and generate a higher proportion of Spike reactive memory B cells, a third vaccination leads to similar levels between the two groups. Furthermore, we show that the third vaccine dose enhances neutralization activity against omicron lineage members BA.1, BA.2 and BA.4/BA.5 and this is further increased following breakthrough infection during the UK omicron wave. These findings are relevant for vaccination strategies in populations where COVID-19 vaccine coverage remains low.

Double trouble - primary biliary cholangitis and coeliac disease in a young female: a case report.

In this case report, we describe a patient who was diagnosed with both Primary Biliary Cholangitis and Coeliac Disease, presenting with symptoms and signs of severe malabsorption and portal hypertension. Extensive workup was done including duodenal and liver biopsies and our patient was ultimately found to have both autoimmune diseases. An association between the two diseases has been reported multiple times during the past four decades with current guidelines recommending screening patients with primary biliary cholangitis for coeliac disease.

Betaine in ameliorating alcohol-induced hepatic steatosis.

Alcohol-associated liver disease (AALD) is one of most common chronic liver diseases. Hepatic steatosis is the earliest stage in AALD pathological spectrum, reversible by alcohol abstinence. Untreated steatosis can progress to steatohepatitis, fibrosis and/or cirrhosis. Considering the difficulties in achieving complete abstinence, challenges in disease reversal at advanced stages, high costs of AALD management and lack of standardised prescribed medications for treatment, it is essential to explore low-cost natural compounds that can target AALD at an early stage and halt or decelerate disease progression. Betaine is a non-hazardous naturally occurring nutrient. Here, we address the mechanisms of alcohol-induced hepatic steatosis, the role of betaine in reversing the effects i.e., its action against hepatic steatosis in animal models and humans, and the associated cellular and molecular processes. Accordingly, the review discusses how betaine restores the alcohol-induced reduction in methylation potential by elevating the levels of S-adenosylmethionine and methionine. It details how betaine reinstates alcohol-induced alterations in the expressions and/or activities of protein phosphtase-2A, FOXO1, PPAR-α, AMPK, SREBP-1c, fatty acid synthase, diacylglycerol transferase-2, adiponectin and nitric oxide. Interrelationships between these factors in preventing de novo lipogenesis, reducing hepatic uptake of adipose-tissue-derived free fatty acids, promoting VLDL synthesis and secretion, and restoring ß-oxidation of fatty acids to attenuate hepatic triglyceride accumulation are elaborated. Despite its therapeutic potential, very few clinical trials have examined betaine's effect on alcohol-induced hepatic lipid accumulation. This review will provide further confidence to conduct randomised control trials to enable maximum utilisation of betaine's remedial properties to treat alcohol-induced hepatic steatosis.

Prognostic role of diuretic failure in determining mortality for patients hospitalized with acute decompensated heart failure.

BACKGROUND: Worsening heart failure (WHF) is defined as persistent or worsening symptoms of heart failure that require an escalation in intravenous therapy or initiation of mechanical and ventilatory support during hospitalization. We assessed a simplified version of WHF called diuretic failure (DF), defined as an escalation of loop diuretic dosing after 48 h, and assessed its effects on mortality and rehospitalizations at 60-days. METHODS: We conducted a multicenter retrospective study between December 1, 2017 and January 1, 2020. We identified 1389 patients of which 6.4% experienced DF. RESULTS: There was a significant relationship between DF and cumulative rates of 60-day mortality and 60-day rehospitalizations (p = 0.0002 and p = 0.0214). After multivariate adjustment, DF was associated with longer hospital stay (p < 0.0001), increased rate of 60-day mortality (p = 0.026), 60-day rehospitalizations (p = 0.036), and a composite outcome of 60-day mortality and 60-day cardiac rehospitalizations (p = 0.018). CONCLUSIONS: DF has a strong relationship with adverse heart failure outcomes suggesting it is a simple yet robust prognostic indicator which can be used in real time to identify high-risk patients during hospitalization and beyond.

Nanodiamond in composite: Biomedical application.

The biocompatibility of materials is the determining factor for them to be applied in biomedical areas. Nanodiamond (ND) has gained increasing interest in this area due to its biocompatibility, ease of surface functionalization and excellent mechanical performance. ND has been widely used to reinforce biopolymers, and the resultant biocomposites have found applications in bone tissue engineering, chemotherapeutic drug delivery, and wound healing. Fluorescent ND, when combined with biopolymers, is serving for bioimaging and sensing applications. Herein, we contribute a description of ND, recent trends in its adoption for biopolymers, functionalization methods, amalgamation techniques of ND with biopolymers, potential applications of these composites in the biomedical field and future perspectives.

Production of rhamnolipid surfactant and its application in bioscouring of cotton fabric.

In the present study, a biosurfactant was synthesized by using a bacterial strain of Pseudomonas aeruginosa in minimal media provided with n-heptadecane as sole carbon source under shake-flask conditions. The biosurfactant was isolated (by acid precipitation, solvent extraction, and rotary evaporation), purified (by column chromatography and TLC), identified (by FAB-MS, FTIR, and 1D-(1)H NMR), and chemo-physical characterized (by tensiometry). Two principal rhamnolipid congeners were identified as dirhamnolipid RRC10C10 and monorhamnolipid RC10C10 with a CMC of 50mg/L. The biosurfactant, hence produced, was applied in sole and in combination with pectinase in scouring of cotton fabric in contrast to conventional scouring agents of NaOH and anionic surfactant SDS. The scoured cotton fabric was investigated for its weight loss, residual oil and grease, wettability, whiteness, and tensile strength. The results were compared both for conventional and biological approaches. The scouring with biosurfactant plus pectinase was equivalent to or better in efficiency than conventional alkaline scouring. The former process is additionally environmentally friendly and bio-compatible. Scanning electron microscopy of cotton fabric showed that the alkaline scouring deteriorates the fabric texture whereas bioscouring with biosurfactant plus pectinase gently removes hydrophobic impurities from the cotton fabric.